摘要
目的探讨沙库巴曲缬沙坦钠(诺欣妥)治疗维持性血液透析(MHD)患者心力衰竭(心衰)的效果。方法选取2019年1月-2021年6月于我院诊治的70例MHD期间心力衰竭患者。按照随机数字表法将其分为A组与B组,每组各35例。A组给予常规治疗,B组给予诺欣妥治疗。对比两组患者的心功能与生化指标。结果治疗6个月后,B组的左室射血分数(LEVF)高于A组,左室舒张末期内径(LVDd),舒张末期室间隔厚度(IVSTd)及左室后壁厚度(LVPWTd)小于A组(P<0.05)。B组的N末端前B型利钠肽(NT-pro BNP)水平低于A组(P<0.05),两组的血清钾水平对比无统计学差异(P>0.05)。结论诺欣妥可改善MHD伴心力衰竭患者的心室重构,促进其心功能恢复,且不会引起高价血症。
Objective:To investigate the effect of sacubitril and valsartan sodium(Entresto)in patients with heart failure(HF)during maintenance hemodialysis(MHD).Methods:70 patients with heart failure during MHD who were treated in our hospital from January 2019 to June 2021 were divided into group A and group B according to the random number table method,with 35 cases in each group.Group A was given routine treatment,and group B was given Entresto treatment.The cardiac function and biochemical indexes of the two groups were compared.Results:After 6months of treatment,the left ventricular ejection fraction(LEVF)in group B was higher than that in group A,and the left ventricular end-diastolic diameter(LVDd),end-diastolic ventricular septal thickness(IVSTd)and left ventricular posterior wall thickness(LVPWTd)were lower than those in group A(P<0.05).The level of Pre-N-terminal B-type natriuretic peptide(NT-probNP)in group B was lower than that in group A(P<0.05),and there was no statistical difference in serum potassium level between the two groups(P>0.05).Conclusion:Entresto improves ventricular remodeling and promotes cardiac function recovery in MHD patients with heart failure without hyperemia.
作者
罗飞
LUO Fei(Affiliated Hospital of Jinggangshan University,Ji'an Jiangxi 343000,China)
出处
《透析与人工器官》
2022年第3期5-7,19,共4页
Chinese Journal of Dialysis and Artificial Organs
